Sign Up Today and Learn More About GRIT Biotechnology Stock
Invest in or calculate the value of your shares in GRIT Biotechnology or other pre-IPO companies through EquityZen's platform.
GRIT Biotechnology Stock (GRBI)
GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors.
About GRIT Biotechnology Stock
Founded
2019
Industries
Internet Services, Payments, Blockchain and Crypto
GRIT Biotechnology Press Mentions
Stay in the know about the latest news on GRIT Biotechnology
Development and characterization of anti-CD19 in vivo CAR T therapy
bioworld • Dec 29, 2025
Shanghai Junshi Biosciences Gets US FDA Approval for Cancer Drug Trial
marketscreener • Dec 15, 2025
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
morningstar • Dec 06, 2025
Vitalgen’s LNP Technology Platform Powers Multiple Partner Pipelines with Positive Progress
einpresswire • Sep 08, 2025
Vitalgen's Cutting-Edge Gene Editing and Delivery Platforms to be Featured at AACR Annual Meeting 2025
einpresswire • Apr 15, 2025
GRIT Biotechnology Management
Leadership team at GRIT Biotechnology
Co-founder and CEO
Yarong Liu
Join now and verify your accreditation status to gain access to:
- GRIT Biotechnology Current Valuation
- GRIT Biotechnology Stock Price
- GRIT Biotechnology Management
- Available deals in GRIT Biotechnology and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- GRIT Biotechnology Cap Table and Funding History by Share Class and Liquidity Preferences
- GRIT Biotechnology Revenue and Financials
- GRIT Biotechnology Highlights
- GRIT Biotechnology Business Model
- GRIT Biotechnology Risk Factors
- GRIT Biotechnology Research Report from SACRA Research
Trading GRIT Biotechnology Stock
How to invest in GRIT Biotechnology stock?
Accredited investors can buy pre-IPO stock in companies like GRIT Biotechnology through EquityZen funds. These investments are made available by existing GRIT Biotechnology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell GRIT Biotechnology stock?
Shareholders can sell their GRIT Biotechnology stock through EquityZen's private company marketplace. EquityZen's network includes over 410K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 50K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
